
AXOGEN INC
AXGNNASDAQTrading Snapshot
- Day Range
- $624.37 β $637.73
- 52-Week Range
- $13.64 β $48.72
- Volume
- $3.22B
- Avg Volume
- $2.23B
- Shares Outstanding
- 53.8M
- Next Earnings
- Oct 17, 2026
Fundamentals Snapshot
- Annual Revenue
- $225M
- Last Q Revenue
- $70M
- P/E Ratio
- β
- P/S Ratio
- 9.9x
- EPS (TTM)
- $-0.68
- Dividend Yield
- β
Why Investors Own AXGN
- βHigh-growth profile β revenue up +27.6% YoY with expanding US Equity exposure.
- βHealthy economics β 73% gross margin and 30% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About AXOGEN INC
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
Otter Score Breakdown
βAnalyst Price Target
βLatest News & Updates
AXOGEN INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift AXGN price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
AXOGEN INC announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.